Which proteins can permanently switch off cancer genes?

Targeting epigenetic regulators to lock genes silent

A recent study shows that blocking specific epigenetic proteins can impose long-lasting repression on oncogenes, effectively shutting off the genetic programs that drive some cancers. The work, carried out by research teams in collaboration between Australian and U.S. institutions, identifies regulatory proteins — the molecular machinery that controls chromatin and gene expression — as lever points that, when perturbed, can push cancer-associated genes into a stably inactive state.

How the approach works

• Epigenetic proteins modify DNA-packaging structures and recruit complexes that permit or block transcription.
• Interfering with those proteins changes the chemical marks and structural context around target genes, making them inaccessible to the transcriptional machinery.
• In some cases, these changes persist after treatment ends, producing durable suppression rather than a transient effect.

Why this could change treatment

Switching off driver genes at the epigenetic level offers the promise of therapies that do more than temporarily shrink tumors: they aim to reprogram cancer cells into a less aggressive state or render them unable to express the genes they need to survive. That could reduce the need for continuous dosing and limit some resistance pathways driven by genetic mutation.

Remaining questions

• It’s still unclear which cancer types and genetic contexts will benefit most, and how durable effects will be in patients versus cell or animal models.
• Delivery, safety, and unintended effects on normal cells must be thoroughly evaluated; epigenetic regulators often play roles across tissues.

Researchers see this as a promising translational route: the next steps are to refine targets, develop precise inhibitors or degraders, and test efficacy and safety in clinical settings.